Case Study

6 minute read

How Highlands Oncology expanded access to oral oncolytics treatment

Learn how Highlands Oncology Group created a one-stop shop for oral oncolytics treatment management by streamlining workflows, offering comprehensive support, and collaborating regionally.

Highlands Oncology Group has taken a proactive approach to meet the rising demand for oral oncolytics. Because of their in-house pharmacy, an improved patient workflow, and partnerships with regional hospitals, Highlands consolidated patient services such as education, medication pickup, and support programs to improve access to oral oncolytics care.


Overview

The challenge

Oral oncolytics are emerging as a powerful tool for certain cancer treatments. As the region’s only network of oncology facilities, Highlands Oncology Group (Highlands) quickly recognized the need to expand infrastructure and staff support to meet growing demand. The facility hoped to improve patient care, reduce avoidable visits to the emergency room, and prevent unwanted early discontinuation of oral oncolytics therapy.1

The organization

Based in northwest Arkansas, Highlands Oncology Group is a 30-physician, 6-location cancer treatment center that provides patients with oncology care close to home. Four of those six locations have an in-house pharmacy that dispenses oral oncolytics.

The approach

In their locations with pharmacies, Highlands consolidated patient services so patients could receive oncology care in the location closest to home, reducing the travel time needed for patient education, medication pickup, and social and financial support. Each in-house pharmacy dispenses limited access oral oncolytics not typically found in a community pharmacy. Oncology patients can visit a pharmacy to access medications and learn more about oral treatments. Highlands also partnered with area hospitals and other organizations to fill gaps in service for patients’ unique needs. This "one-stop shop" approach is convenient for both patients and providers and has a positive impact on patient care, specifically patient adherence.

The result

By creating a streamlined workflow for their in-house pharmacy and filling gaps in care, Highlands improved access to oral oncolytics care. Between 2024 and 2025, Highlands has served about 1,900 oral oncolytics patients and obtained funding and other assistance for 800.2

1,900
Oral oncolytic patients served between 2024 and 2025

Approach

How Highlands created a one-stop shop for oral oncolytics treatment

To improve patient care, reduce avoidable ED visits, and help prevent early discontinuation of oral oncolytics, Highlands consolidated patient services in each of their six locations and developed an improved pharmacy workflow.

The 3 elements

Highlands Oncology started by mapping the patient journey, including which providers interact with patients at each stage of the care journey, the reason for each interaction, and the frequency of interactions. Using tacks and string on a board, leaders at Highlands marked each point in the patient experience within and outside their facility. Creating a visual representation of the patient journey allowed Highlands to identify when patients encountered each member of their cross-functional team — including pharmacists, financial advocates, providers, and triage nurses — pinpoint where patients were facing obstacles, and formulate solutions to address gaps in care.

As a result of these discussions, Highlands adjusted their in-house pharmacy workflow to create the smoothest patient experience possible. To achieve this, the clinical and pharmacy teams work together to educate patients, help with coverage and financing issues, and follow up to help manage symptoms and side effects when appropriate.

Highlands Oncology Group’s improved workflow for oral oncolytics

The clinical team — including doctors, nurses, and pharmacists — selects the best treatment plan based on patient characteristics, approved treatment guidelines, insurance coverage, and available funding. After discussing the treatment plan with the patient, the team orders the oral oncolytics prescription.

That same day, the patient meets with the pharmacy team, who educates them about medication use, potential side effects, and pickup.

At the same time, pharmacists and nurses start the prior authorization and payment process.

Financial advocates search for financial assistance for patients and set up transportation and translation services, if necessary.

Once finances are set, the patient picks up medications from the in-house pharmacist, who further educates the patient about their medication.

If the patient is getting a drug through a manufacturer’s program, the pharmacy staff educates the patient about the process and follow-up to ensure the patient received the drug.

Over time, a triage team of nurses monitors patient reports of symptoms and side effects via alerts on an electronic platform. If necessary, the triage team works with the clinical team to schedule a patient visit.

The clinical team continues to monitor side effects and adherence, adjusting the treatment plan as necessary.

For example, to mitigate delays in the patient’s first prescription fill, Highlands applies for prior authorizations and financial assistance immediately and coordinates closely with providers and patients about the process. The pharmacy works with manufacturers to explore approaches that may help patients begin therapy as quickly as possible.

Also, while the pharmacy doesn’t ship prescriptions, pharmacists try to schedule prescription pickup on the same day as patient visits to reduce patient travel time.

Finally, in response to concern that patients might fall off the radar after receiving their prescriptions, Highlands now uses an interface that allows nurses on the triage team to monitor patients’ concerns about symptoms and side effects from oral oncolytics. If a patient reports a concern, nurses contact them, track their symptoms, and refer the issue to the care team so the treatment plan can be adjusted, if necessary.

Highlands reported that the mapping process improved patient outcomes. In addition, it formed the basis of quality improvement projects that use real-world data to refine care strategies and allocate resources where they are most needed.

Questions programs might ask themselves

  • Which team members at your organization interact with patients?
  • What locations within your facility will patients visit throughout their care journey?
  • What technologies will patients use or need access to while on their care journey?

As the only oncology facility in the region, Highlands recognized the importance of facilitating patient access to care in ways that reflect the region and social drivers of health. In Highlands’ case, patients were experiencing two obstacles that were significantly impacting their medication adherence and persistence.

First, some patients struggled to get to appointments due to a lack of transportation. In response, Highlands partnered with Hope Cancer Resources — a community-based nonprofit dedicated to providing wrap-around cancer support services in Arkansas — to provide complimentary transportation services for five of their six facilities. The service can help patients within a 50-mile radius attend appointments and access their medications, regardless of socioeconomic status. Hope Cancer Resources staff are also available at the hospital to help patients with other access to care issues.

Second, Highlands staff noticed that some Spanish-speaking patients — a large population within their community — faced a language barrier when communicating with their care teams. In response, Highlands invested in a team of translators to help providers communicate effectively with those patients.

Both services enable Highlands’ patient population to access their cancer treatments and provide additional resources to support adherence. After investing in infrastructure and support services that target the unique needs of their population, Highlands reported improved health outcomes, reduced costs related to nonadherence, and increased health equity.

To encourage a seamless patient experience and coordinated treatment across healthcare providers and settings, Highlands partnered with area hospitals and nonprofits that could potentially help meet individual patient needs, improve patient access, boost outcomes, and align with broader health initiatives like value-based care.3

Highlands started by building relationships with the leaders of nearby hospitals and leveraging connections. For example, one large hospital system in the region had undertaken an approach to healthcare delivery that emphasized regional and local collaboration. When approached by the hospital system, the Highlands team decided to work closely with them to contribute to wrap-around care offerings for patients in northwest Arkansas. The oncology facility now partners with three hospitals in northwest Arkansas that are also integrated with Highlands’ system. In addition, certain providers from other systems join the multidisciplinary teams at Highlands once per week to conduct rounds with the Highlands staff, helping to ensure patient needs are met.

Highlands works with external partners to provide mental health counseling and support groups, coordinate transportation to and from appointments, and secure grants and other funding2 to support patients taking oral oncolytics, which are not always covered by insurance.

Results

Current state

Through their in-house pharmacy and updated workflow, Highlands Oncology Group focused on improving access to oral oncolytic medications and closing gaps in care.

60%
Of oral oncolytics prescribed were filled at Highlands in 2024*

*See endnote 4.

1,900
Patients were triaged by the oral oncolytic team from August 2024 to August 2025
2,600
Prescriptions were triaged by the oral oncolytic team from August 2024 to August 2025
800
Grants and funding from patient assistance programs were obtained from August 2024 to August 2025*

*See endnote 2.

Looking to the future

In June 2025, Highlands received a 2025 Association of Cancer Care Centers (ACCC) Innovator Award for the creation of their remote patient monitoring model.5 Over the next two years, Highlands hopes to further refine their scalable remote patient monitoring model. To enable this work, Highlands is focused on investigating which data is most helpful to identify care gaps and monitor the progress of their program.

1 Unless otherwise noted, all information in this case study came from Advisory Board interviews with two officials from the Highland Oncology Group’s leadership team.

2 Grants, funding, and other assistance obtained for patients are completely independent of Pfizer.

3 Southwick R. Planning to transform health care in Arkansas. Chief Healthcare Executive. February 10, 2025.

4 Highlands attempts to fill all oral oncolytic prescriptions, but transfers prescriptions when a patient’s PBM prevents access to Highlands or the patient is getting the drug at no cost through a manufacturer-sponsored program.

5 Radwan R. Improving Care Between Clinic Visits: A Sustainable Model for Remote Patient Monitoring. Association of Cancer Care Centers. June 10, 2025.


About the sponsor

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. Good health is vital to all of us and finding sustainable solutions to the most pressing health care challenges of our world cannot wait. That's why we at Pfizer are committed to applying science and our global resources to improve health and well-being at every stage of life. For more information, please visit www.pfizer.com.

This case study is sponsored by Pfizer, an Advisory Board member organization. Representatives of Pfizer helped select the topics and issues addressed. Advisory Board experts maintained final editorial approval, and conducted the underlying research independently and objectively. Advisory Board does not endorse any company, organization, product or brand mentioned herein.

To learn more, view our editorial guidelines.


Sponsored by

This case study is sponsored by Pfizer. Advisory Board experts conducted the underlying research independently and objectively.

Learn more about Pfizer


Download

SPONSORED BY

INTENDED AUDIENCE

AFTER YOU READ THIS
  • You'll know how consolidating services can improve access to oral oncolytics care.
  • You'll understand how to map and adjust workflows to meet patient needs.

AUTHORS

Michaela Dipillo

Research analyst

Serena Bernthal-Jones

Director, Custom research

Jennifer Fierke

Senior writer and editor, Sponsorship

TOPICS

INDUSTRY SECTORS

Don't miss out on the latest Advisory Board insights

Create your free account to access 1 resource, including the latest research and webinars.

Want access without creating an account?

   

You have 1 free members-only resource remaining this month.

1 free members-only resources remaining

1 free members-only resources remaining

You've reached your limit of free insights

Become a member to access all of Advisory Board's resources, events, and experts

Never miss out on the latest innovative health care content tailored to you.

Benefits include:

Unlimited access to research and resources
Member-only access to events and trainings
Expert-led consultation and facilitation
The latest content delivered to your inbox

You've reached your limit of free insights

Become a member to access all of Advisory Board's resources, events, and experts

Never miss out on the latest innovative health care content tailored to you.

Benefits include:

Unlimited access to research and resources
Member-only access to events and trainings
Expert-led consultation and facilitation
The latest content delivered to your inbox

This content is available through your Curated Research partnership with Advisory Board. Click on ‘view this resource’ to read the full piece

Email ask@advisory.com to learn more

Click on ‘Become a Member’ to learn about the benefits of a Full-Access partnership with Advisory Board

Never miss out on the latest innovative health care content tailored to you. 

Benefits Include:

Unlimited access to research and resources
Member-only access to events and trainings
Expert-led consultation and facilitation
The latest content delivered to your inbox

This is for members only. Learn more.

Click on ‘Become a Member’ to learn about the benefits of a Full-Access partnership with Advisory Board

Never miss out on the latest innovative health care content tailored to you. 

Benefits Include:

Unlimited access to research and resources
Member-only access to events and trainings
Expert-led consultation and facilitation
The latest content delivered to your inbox
AB
Thank you! Your updates have been made successfully.
Oh no! There was a problem with your request.
Error in form submission. Please try again.